Advertisement

Topics

Search Results for "Orthophoenix Llc Medtornic Kyphon Patents"

19:38 EST 9th February 2016 | BioPortfolio

Matching Channels

Biosuperior Antibodies

After biosimilar versions of therapeutic proteins have become reality in Europe and in the US, now it’s the turn of therapeutic antibodies to be in the line of fire. Patents of the first wave of...

Tumor Necrosis Factor TNF Products

Tumor Necrosis Factor (TNF) and TNF receptor antagonists and agonists used to treat TNF-mediated inflammatory diseases such as rheumatoid arthritis or to treat cancer. TNF blockers are the commerc...

Coagulation Factors

Fourteen different blood coagulation factors are present in the body. Each plays a crucial role in the process described above. Some work to increase the activity level of the other factors while so...

Matching News

Dipexium Pharma gets Locilex patents in Australia and NZ

Dipexium Pharmaceuticals (NASDAQ:DPRX) said that Australia and New Zealand have issued new Locilex patents, with expiry dates in June 2033. The patents’ claims are directed to a novel formulatio...

Bass challenges Acorda patents again

Kyle Bass' Coalition for Affordable Drugs filed three new inter partes review (IPR) petitions challenging patents covering Ampyra dalfampridine from Acorda Therapeutics Inc. (NASDAQ:ACOR) on grounds o...

Patents prompting ‘rebirth’ of innovation in industry

Seven pharma companies have been rated among the world’s 100 most innovative companies, according to Thomson Reuters. The business intelligence firm compiled a list of the top 100 global innovators ...

GMOs and Patents: Part 2 – Lawsuits against Farmers

This is the second of three posts examining the topic of GMOs and patents. The first post in the series provided an overview on the topic of patents and described the concept of “terminator genes...

GMOs and Patents: Part 1 – Terminator Genes

This is the first of three posts examining the topic of GMOs and patents. As the first post in the series, I’ll provide an overview on the topic of patents and will describe the concept of ̶...

GMOs and Patents: Part 3 – Lawsuits for inadvertent contamination

This is the third and final post in a series examining the topic of GMOs and patents. The first post provided an overview on the topic of patents and described the concept of “terminator genes”....

SHIRE PLC - Appeals Court Affirms Shire's Patents

Appeals Court Affirms Shire's Vyvanse® (lisdexamfetamine dimesylate) Patents Are Valid Until 2023 Ruling bars generic versions of Vyvanse from entering market until patents expire Lexington, Mass....

The Trans-Pacific Partnership: Changes for patents and pharmaceuticals?

Changes may be on the horizon for Canada’s legal and regulatory regime for patents and pharmaceuticals. Included in the Trans-Pacific Partnership Agreement (TPP), concluded Oct. 5, 2015 are negotiat...

Matching PubMed Articles

Novel methods to optimize the effects of transcranial direct current stimulation: a systematic review of transcranial direct current stimulation patents.

Transcranial direct current stimulation (tDCS) is a neuromodulatory technique that has been extensively studied. While there have been initial positive results in some clinical trials, there is still ...

Searching bioremediation patents through Cooperative Patent Classification (CPC).

Patent classification systems have traditionally evolved independently at each patent jurisdiction to classify patents handled by their examiners to be able to search previous patents while dealing wi...

FFA4/GPR120 agonists: a survey of the recent patent literature.

FFA4/GPR120, a member of the rhodopsin family of G-protein-coupled receptors (GPCRs), is becoming an important target for therapeutic intervention in several areas of disease, including metabolic dise...

Gastroretentive carrier systems in the delivery of therapeutic actives: an updated patent review.

Gastroretentive drug-delivery systems have the potential to prolong the gastric retention time and provide controlled/sustained release of a drug at the absorption site, thereby improving the bioavail...

Newer patents in antimycobacterial therapy.

Tuberculosis caused by Mycobacterium tuberculosis is a global health emergency. This deadly disease has far-reaching social and economic implications. Diseased individuals need prolonged polypharmacy ...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement